Market Closed -
Japan Exchange
02:00:00 2024-05-31 am EDT
|
5-day change
|
1st Jan Change
|
1,777
JPY
|
+4.28%
|
|
+6.22%
|
-.--%
|
Fiscal Period: March |
2025
|
2026
|
---|
Capitalization
1 |
8,912
|
-
|
Enterprise Value (EV)
1 |
8,912
|
8,912
|
P/E ratio
|
14.3
x
|
13.3
x
|
Yield
|
0.79%
|
0.79%
|
Capitalization / Revenue
|
1.89
x
|
1.74
x
|
EV / Revenue
|
1.89
x
|
1.74
x
|
EV / EBITDA
|
7.5
x
|
6.28
x
|
EV / FCF
|
-35.1
x
|
-47.2
x
|
FCF Yield
|
-2.85%
|
-2.12%
|
Price to Book
|
1.68
x
|
1.51
x
|
Nbr of stocks (in thousands)
|
5,015
|
-
|
Reference price
2 |
1,777
|
1,777
|
Announcement Date
|
-
|
-
|
Fiscal Period: March |
2024
|
2025
|
2026
|
---|
Net sales
1 |
4,770
|
4,717
|
5,130
|
EBITDA
1 |
-
|
1,188
|
1,418
|
EBIT
1 |
596
|
799
|
891
|
Operating Margin
|
12.49%
|
16.94%
|
17.37%
|
Earnings before Tax (EBT)
1 |
635
|
830
|
907
|
Net income
1 |
384
|
618
|
671
|
Net margin
|
8.05%
|
13.1%
|
13.08%
|
EPS
2 |
92.43
|
124.5
|
133.7
|
Free Cash Flow
1 |
-
|
-254
|
-189
|
FCF margin
|
-
|
-5.38%
|
-3.68%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
Dividend per Share
2 |
14.00
|
14.00
|
14.00
|
Announcement Date
|
5/15/24
|
-
|
-
|
Fiscal Period: March |
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-254
|
-189
|
ROE (net income / shareholders' equity)
|
12.1%
|
14.5%
|
12%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
Book Value Per Share
2 |
803.0
|
1,056
|
1,176
|
Cash Flow per Share
|
164.0
|
-
|
-
|
Capex
1 |
-
|
186
|
1,167
|
Capex / Sales
|
-
|
3.94%
|
22.75%
|
Announcement Date
|
5/15/24
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -.--% | 56.68M | | +40.73% | 739B | | +32.83% | 598B | | -6.30% | 353B | | +15.15% | 318B | | +4.05% | 285B | | +15.00% | 240B | | +9.78% | 210B | | -5.52% | 206B | | +6.17% | 164B |
Other Pharmaceuticals
|